Panic Disorder

... ottawasun.com - Senators 05-06 - Senators 1st, Canada 2nd Monday February 27 2006 Click to enlarge !

-Get ready to help us choose the winners in the Sun's Model Search 2006...- Get ready to help us choose the winners in the Sun's Model Search 2006 !

- !

- Current Conditions Clear-20oC Full Forecast Ottawasun.COM Home News Special Features Sports Winter Games Columnists Hockey Senators Football Baseball Other Sports Showbiz The Scene Comment Columnists Lifestyle Money Photo Galleries SUN Drive Contests Find a Business Type Province AB BC MB NB NL NS NT NU ON PE QC SK YT Name City Find a Person Winter Games Winterlude 2006 Canadian Figure Skating Champs.

Bell Capital Cup 2006 Ottawa's 150th SUNshine Girl Classified Extra Jobboom Autonet Homes for Sale Career Connection Lotteries Comics Crossword Horoscopes TV Listings Movie Listings Subscriptions Advertising News Research About Us Contact Us Sun, February 26, 2006 Senators 1st, Canada 2nd Stanley Cup's more important than Olympic gold By ERIN NICKS, OTTAWA SUN "If you just sit back and record what you see; the tragic and exquisite are the same to some degree.

But most events depict a common theme: There's far more disorder than there is harmony." - Bad Religion's Mediocrity - Amediocre performance, combined with non-existent offense and a complete lack of cohesion.

That description would sum up the Canadian men's Olympic hockey team.

Meanwhile, the Canadian media have already deemed it futile to analy...

... CANOE - SLAM!

Sports - Hockey NHL - Ottawa: Stanley Cup's more important than Olympic gold !

- Sun, February 26, 2006 FANTASY '05 SCOREBOARD NEWS HOCKEY GALLERY PUCKMASTER ASK DR.

HOCKEY FREE AGENTS NHL PREVIEW STATS PLAYER BIOS MOVEMENTS COLUMNISTS NHL Teams Anaheim Atlanta Boston Buffalo Calgary Carolina Chicago Colorado Columbus Dallas Detroit Edmonton Florida Los Angeles Minnesota Montreal Nashville New Jersey N.Y.

Islanders N.Y.

Rangers Ottawa Philadelphia Phoenix Pittsburgh San Jose St.

Louis Tampa Bay Toronto Vancouver Washington Statistics DAILY Goals Assists Plus/Minus PPG SHG SOG Wins Losses Shutouts SCORING All Stats Points Goals Assists PP Goals PP Assists PP Points SH Goals SH Assists SH Points Game Winners Game Tying Goals Shots Shooting % Rookies Defencemen Plus/Minus Hat Tricks Streaks GOALTENDING All Teams Goals Ag.

Avg.

Shutouts Wins Save % Hockey Plus Player Bios Movements Injuries FIND A PLAYER: DAILY SKED PRESEASON SKED DAILY LEADERS EAST STANDINGS WEST STANDINGS Hockey Index Schedules Daily Regular Season Playoff East Conference West Conference October November December January February March April Free Agents News Buyouts Unrestricted Restricted NHL in Europe NHL Extra The Puckmaster Ask Dr.

Hockey Player of Week Offseason Updates Tickets Injuries Transactions !

-Trades- More Hockey Juniors AHL CIS NCAA Women WHA ECHL CHL Review NHL Playoffs NHL Entry Draft World Championship World Cup Trades All-Star Games Top Prospects Expansion Gretzky F...

...MediciNova Announces Completion of Enrollment in a Phase II/III Generalized Anxiety Disorder Trial With MN-305: Financial News - Yahoo!

Finance Yahoo!

My Yahoo!

Mail Welcome, Guest [Sign Out, My Account] Finance Home - Help HomeInvestingNews & CommentaryRetirement & PlanningBanking & CreditLoansTaxesSpecial EditionsColumnistsPersonal FinanceInvesting IdeasMarketsCompany FinancesProvidersGet QuotesSymbol LookupFinance Search Press ReleaseSource: MediciNova, Inc.

MediciNova Announces Completion of Enrollment in a Phase II/III Generalized Anxiety Disorder Trial With MN-305Monday February 27, 1:30 am ET SAN DIEGO, Feb.

27 /PRNewswire/ - MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced completion of enrollment in its Phase II/III clinical trial of MN-305 in 416 patients with Generalized Anxiety Disorder (GAD).

"MN-305 may offer effective treatment of GAD without the side effects (e.g., increased risk of suicide, sexual dysfunction, agitation) associated with antidepressants currently used to treat anxiety disorders such as GAD," said Yuichi Iwaki, M.D., Ph.D., Executive Chairman and Acting CEO of MediciNova, Inc.

"Completion of enrollment in a large, pivotal-design trial demonstrates MediciNova's commitment to advancing our clinical programs through at least the proof-of-concept stage and into Phase III clinical testing."In December 2004, MediciNova in...